The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total pay increase, according (PDF) to a securities filing.

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Since that time, though, demand for these products has declined, and that's resulted in lower revenue and a drop in the Pfizer share price. Right now, as an investor, you may be wondering if you ...

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...

Pfizer Canada’s IXIFI (infliximab for injection) will be available in Canada as of April 1, 2025. IXIFI is a biosimilar to Remicade (infliximab). It was approved by ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get ...

Vedotin is the payload in a clutch of ADCs that Pfizer acquired in the Seagen buyout, including the approved products Adcetris, Padcev and Tivdak. Summit's stock price dropped by nearly 15% during ...